Mohamed Shanavas1, Hans A Messner2, Suzanne Kamel-Reid3, Eshetu G Atenafu4, Vikas Gupta2, John Kuruvilla2, Dennis Dong Hwan Kim2, Jieun Uhm2, Anna Lambie2, Laura Ellis2, Jeffrey H Lipton2. 1. Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: mohamed.shanavas@uhn.ca. 2. Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 3. Department of Pathology, University Health Network, Toronto, Ontario, Canada. 4. Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario Canada.
Abstract
BACKGROUND: Donor lymphocyte infusion (DLI) and tyrosine kinase inhibitors (TKIs) are the 2 standard treatment options in chronic myeloid leukemia (CML) that relapses after hematopoietic cell transplantation (HCT), but reports comparing long-term outcomes of these modalities are rare. PATIENTS AND METHODS: A total of 46 patients were treated with either DLI (n = 28) or TKIs (n = 18) during a first relapse of CML after HCT between 1993 and 2012. The stage of relapse was the chronic phase in 37 patients and the advanced phase in 9 patients. All patients had myeloablative conditioning without T-cell depletion during HCT. The median interval between HCT and treatment for relapse was 34 (range, 2-197) months. RESULTS: At a median follow-up of 146 and 70 months, respectively, 32% of the DLI group and 33% of the TKI group had died. Six (21%) patients initially treated with DLI received TKIs during a second relapse. In multivariable analyses, DLI was associated with inferior overall survival (OS) (hazard ratio [HR], 37.4; 95% confidence interval [CI], 2.2-625.4; P = .01), shorter failure-free survival (FFS) (HR, 21.15; 95% CI, 1.8-251; P = .02), higher cumulative incidence of failure (CIF) (HR, 19.5; 95% CI, 1.6-236.5; P = .02), and increased incidence of treatment-induced graft vs. host disease (GVHD) (68% vs. 6%; P = .001). CONCLUSION: TKIs appear better than DLI in chronic-phase relapses after myeloablative non-T-cell-depleted HCT. Outcomes were poor in advanced-phase relapses irrespective of treatment modality.
BACKGROUND:Donor lymphocyte infusion (DLI) and tyrosine kinase inhibitors (TKIs) are the 2 standard treatment options in chronic myeloid leukemia (CML) that relapses after hematopoietic cell transplantation (HCT), but reports comparing long-term outcomes of these modalities are rare. PATIENTS AND METHODS: A total of 46 patients were treated with either DLI (n = 28) or TKIs (n = 18) during a first relapse of CML after HCT between 1993 and 2012. The stage of relapse was the chronic phase in 37 patients and the advanced phase in 9 patients. All patients had myeloablative conditioning without T-cell depletion during HCT. The median interval between HCT and treatment for relapse was 34 (range, 2-197) months. RESULTS: At a median follow-up of 146 and 70 months, respectively, 32% of the DLI group and 33% of the TKI group had died. Six (21%) patients initially treated with DLI received TKIs during a second relapse. In multivariable analyses, DLI was associated with inferior overall survival (OS) (hazard ratio [HR], 37.4; 95% confidence interval [CI], 2.2-625.4; P = .01), shorter failure-free survival (FFS) (HR, 21.15; 95% CI, 1.8-251; P = .02), higher cumulative incidence of failure (CIF) (HR, 19.5; 95% CI, 1.6-236.5; P = .02), and increased incidence of treatment-induced graft vs. host disease (GVHD) (68% vs. 6%; P = .001). CONCLUSION: TKIs appear better than DLI in chronic-phase relapses after myeloablative non-T-cell-depleted HCT. Outcomes were poor in advanced-phase relapses irrespective of treatment modality.
Authors: Joshua F Zeidner; Marianna Zahurak; Gary L Rosner; Christopher D Gocke; Richard J Jones; B Douglas Smith Journal: Leuk Lymphoma Date: 2014-06-16
Authors: Sarah Schmidt; Ying Liu; Zhen-Huan Hu; Kirsten M Williams; Hillard M Lazarus; Ravi Vij; Mohamed A Kharfan-Dabaja; Guillermo Ortí; Peter H Wiernik; Daniel Weisdorf; Rammurti T Kamble; Roger Herzig; Baldeep Wirk; Jan Cerny; Ulrike Bacher; Naeem A Chaudhri; Sunita Nathan; Nosha Farhadfar; Mahmoud Aljurf; Usama Gergis; Jeffrey Szer; Sachiko Seo; Jack W Hsu; Richard F Olsson; Dipnarine Maharaj; Biju George; Gerhard C Hildebrandt; Vaibhav Agrawal; Taiga Nishihori; Hisham Abdel-Azim; Edwin Alyea; Uday Popat; Ronald Sobecks; Bart L Scott; Jennifer Holter Chakrabarty; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2020-02-14 Impact factor: 5.742
Authors: Agnieszka Piekarska; Lidia Gil; Witold Prejzner; Piotr Wiśniewski; Aleksandra Leszczyńska; Michał Gniot; Mieczysław Komarnicki; Andrzej Hellmann Journal: Ann Hematol Date: 2015-07-29 Impact factor: 3.673